Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma

Creative Commons License

Gurler F., GÜVEN D. C., Aydemir E., SÜTCÜOĞLU O., Inci B. K., ARIK Z., ...More

TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.5, pp.1559-1568, 2022 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 52 Issue: 5
  • Publication Date: 2022
  • Doi Number: 10.55730/1300-0144.5496
  • Journal Name: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.1559-1568
  • Keywords: FLOT, gastric cancer, gastroeosephageal cancer, modified DCF, PHASE-II, SYSTEMIC CHEMOTHERAPY, MODIFIED DOCETAXEL, PLUS CHEMOTHERAPY, FLUOROURACIL DCF, JUNCTION CANCER, CISPLATIN, 5-FLUOROURACIL, OXALIPLATIN, LEUCOVORIN
  • Hacettepe University Affiliated: Yes

Abstract

Background/aim: The aim of our study was to compare the efficacy and the safety of the FLOT and the modified DCF (mDCF) regimens in patients with metastatic gastric (GC) and gastroesophageal junction (GEJ) adenocarcinoma as first-line treatment.